He highlights a 2007 American Pain Foundation brainstorming session that noted, "encourage patients to advocate for their rights … let women educate women in their natural settings (e.g., Tupperware parties, garden groups, e-cards)."
See the American Pain Foundation session notes (p. 102) and more in the Oklahoma lawsuit against Purdue and other industry players: industrydocuments.ucsf.edu/d…
This image of a marquee board reading “Don't worry everything is going to be amazing,” with a pile of pills on top of the picture, was used in a 2015 DEA Compliance presentation for Teva. See in #OIDAimages: images.oida-resources.jhu.ed…
#Opioid#Archive documents are featured in this year's shared task! We look forward to seeing how participants innovate in computational linguistics and the social sciences to address a public health question using OIDA documents.
The Endo #opioids collection reached its first 1 million documents milestone! Check out the latest sales reports, slide decks, DEA communications and more. industrydocuments.ucsf.edu/o…
ALT Slide describing Key Issues, Strategy and Tactics for promoting Opana ER
Use of a Critical Constructivist, Community-Engaged Approach to Understand Commercial Determinants of Breast Cancer: The Situational Scoping Method mdpi.com/3639738#mdpiijerph via @IJERPH_MDPI
“Are you seeing your patients or your fears?” was one of several messaging concepts Teva tested in 2014 for their OraGuard abuse deterrent technology. See in #OIDAimages: images.oida-resources.jhu.ed…
Testing feedback suggested that “the message is all about fear and the negative issues swirling around the prescribing of opioids. Unfortunately, it doesn’t necessarily emphasize that OraGuard is the solution to those fears.”
Teva contributed “financial support, clinical input and other expertise” to the Discovery Channel’s 2015 “Pain Matters” documentary, alongside the company's launch of PainMatters.com. See more in #OIDAimages: images.oida-resources.jhu.ed…
See how the documentary screening fit into Teva’s overall plans for the American Academy of Pain Medicine’s 2015 annual meeting: industrydocuments.ucsf.edu/d…
Actiq was commonly referred to as a “fentanyl lollipop.” It and other TIRF (Transmucosal Immediate-Release Fentanyl medicines) were discontinued in 2024. See this image and similar others in #OIDAimages: images.oida-resources.jhu.ed…
Check out Dan Kabella's use of the UCSF Makers Lab to recreate the handle of the Actiq fentanyl lollipop using candy (without fentanyl) as a teaching tool: library.ucsf.edu/news/meet-t…